Home・Elenco Azioni・InflaRx NV

InflaRx NV

Chiusa

1.76 1.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.72

Massimo

1.81

Metriche Chiave
By Trading Economics
Entrata	3.2M -5.7M
EPS	-0.08
Margine di Profitto	16,200.567
Dipendenti	65
EBITDA	8.5M -5.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+366.86% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	104M 258M
Apertura precedente	0.61
Chiusura precedente	1.76

InflaRx NV Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2026, 23:56 UTC

Baidu Inc. shares are roughly flat in after-market trading, remaining near unchanged since Tuesday's close and positioned around the midpoint of its one-month range.

4 ago 2026, 23:56 UTC

Ziff Davis Inc shares are lower during after-market hours, with no specific news identified to explain the movement. The stock fluctuated earlier in the session.

4 ago 2026, 23:56 UTC

Centene Corp shares are higher in after-market hours, continuing a recent upward trend amid positive market sentiment following a narrowing U.S. trade deficit.

4 ago 2026, 23:56 UTC

Insulet Corp shares are lower in after-market hours, showing little change since Tuesday's close amid a lack of specific company news.

4 ago 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

4 ago 2026, 23:56 UTC

Xcel Energy shares advanced in after-market trading, reaching a high of 0.60% above Tuesday's close, though still below the 20-day moving average.

4 ago 2026, 23:56 UTC

Nasdaq Inc. shares showed routine trading activity during after-market hours, remaining roughly flat since Tuesday's close and positioned above its 20-day moving average.

4 ago 2026, 23:56 UTC

Correlated Moves

ETF Constituents

Macro News

The iShares U.S. Aerospace & Defense ETF is trading higher in after-market hours, supported by positive earnings from technology stocks and geopolitical developments.

4 ago 2026, 23:56 UTC

Darling Ingredients Inc shares are higher in after-market trading, rebounding from earlier session lows. No specific news was identified to explain the movement.

4 ago 2026, 23:56 UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund traded near unchanged in after-market hours, supported by positive contributions from Walmart, Costco, and PepsiCo.

4 ago 2026, 23:56 UTC

Public Service Enterprise Group Inc shares are modestly higher in after-market hours. No specific company news was identified to explain the movement.

4 ago 2026, 23:56 UTC

TE Connectivity Ltd. shares are lower in after-market trading, retracing from earlier gains. The stock remains above its 20-day moving average.

4 ago 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, moving lower since Tuesday's close. The stock remains above its 20-day moving average.

4 ago 2026, 23:56 UTC

TAL Education Group shares are higher in after-market hours, recovering slightly after three consecutive sessions of decline and remaining above the 20-day moving average.

4 ago 2026, 23:56 UTC

Packaging Corp of America shares were roughly flat in after-market hours, remaining above their 20-day moving average following three consecutive higher sessions.

4 ago 2026, 23:56 UTC

Regions Financial Corp shares are higher in after-market hours, continuing a trend of strength following four consecutive sessions of gains.

4 ago 2026, 23:56 UTC

Fuelcell Energy Inc shares are lower in after-market trading, with no specific company news identified to explain the decline following Tuesday's close.

4 ago 2026, 23:56 UTC

MACOM Technology Solutions Holdings Inc. shares are lower in after-market trading, reflecting routine fluctuations and positioning below the 20-day moving average.

4 ago 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4 ago 2026, 23:56 UTC

MKS Instruments Inc shares are lower in after-market hours, reflecting notable weakness as they remain significantly below their 20-day moving average.

4 ago 2026, 23:56 UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

4 ago 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4 ago 2026, 23:56 UTC

The US 10Y Treasury Bond Index is trading roughly flat. The U.S. trade deficit narrowed to $73.3 billion in June from $77.6 billion in May.

4 ago 2026, 23:56 UTC

Whirlpool Corp shares are trading lower in after-market hours, with no specific news identified to explain the movement. They remain near the upper end of their one-month range.

4 ago 2026, 23:56 UTC

CRISPR Therapeutics AG shares are lower in after-market trading, following a volatile session with no specific news identified to explain the movement.

4 ago 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 ago 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4 ago 2026, 23:56 UTC

Ultra Clean Holdings Inc. shares are higher in after-market trading, despite no specific company news identified. The broader market reflects a narrowing U.S. trade deficit.

4 ago 2026, 23:52 UTC

Correlated Moves

Teradyne Inc. shares gained in after-market trading, reflecting positive sentiment in U.S. markets amid easing inflation concerns related to oil supply negotiations.

4 ago 2026, 23:52 UTC

Brazil's upcoming inflation report on August 11, 2026, is poised to influence central bank policy amid rising energy prices and declining manufacturing activity.

Confronto tra pari

Modifica del prezzo

InflaRx NV Previsione

Obiettivo di Prezzo

By TipRanks

366.86% in crescita

Previsioni per 12 mesi

Media 8.17 USD 366.86%

Alto 14 USD

Basso 4 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per InflaRx NV - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a InflaRx NV - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.